Nerve InjuryNCT07403695
Photobiomodulation Therapy on Nerve Repair Using Red and Infra-red Diode Lasers
A study testing 635 wavelength and 980 wavelength in people with Nerve Injury, run by mona oraby at 1 site in Egypt.
Trial summary
Peripheral nerve injury is a major concern that drastically affects the patient's quality of life. Nowadays, several treatment options are available, including medical treatments, surgical intervention, and others. Read more about this study
- Who is it for?
- Ages 20 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Nerve Injury
- What is being tested?
- 635 wavelength and 980 wavelength
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteEgypt
- Study dates
- 18 Mar 2025to 18 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Patient aged range from 20-50 years old
- Patient suffering from nerve injury in the maxillofacial region for a period of 6 months or more without improvement.
Who cannot join
- 1- Patient had undergone micro-neurosurgery to correct neurosensory deficit.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparison Between Photobiomodulation Therapy on Nerve Repair Using Red and Infra-red Diode Lasers in Maxillofacial Region (A Randomized Clinical Trial)
Peripheral nerve injury is a major concern that drastically affects the patient's quality of life. Nowadays, several treatment options are available, including medical treatments, surgical intervention, and others. However, the trending photobiomodulation effect of laser therapy is attracting many dental professionals due to its promising results on nerve rehabilitation.
The study is intended to assess and compare laser photobiomodulation using red and infra-red diode lasers on the repair of nerve injury in the maxillofacial region.
- Conditions
- Nerve Injury
- Being tested
- 635 wavelength, 980 wavelength
- Keywords
- laser therapy, photobiomodulation, nerve injury
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
635 wavelengthDevice
635 wavelength laser
980 wavelengthDevice
980 wavelength laser
| Study group | Role | What they receive |
|---|---|---|
| 635 wavelength | Experimental | Not described Receives: Device: 635 wavelength |
| 980 wavelength | Active comparator | Not described Receives: Device: 980 wavelength |
What is being measured
The primary outcome is the main question the study is designed to answer.
visual analogue scale
from 1- 10
1 means no pain 10 means worst pain
Measured: 1,2,4,8,12 weeks
Secondary outcomes (1)
clinical neurosensory test
from S0 to S4 S0 means worst neurosensory function S4 full recovery for neurosensory function
Measured: 2,4,8,12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Feb 2026
- Study start18 Mar 2025
- Primary completion18 Jan 2026
- Study completion18 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Nerve InjuryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- mona oraby
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, mona oraby, Alexandria University
- Investigators
- Mona S Oraby, Principal investigator, Alexandria University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07403695
- Sponsor's protocol ID
- 00010556- 0008839
- Status last verified
- Feb 2026
- First submitted
- 5 Feb 2026
- Last updated
- 12 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison Between Photobiomodulation Therapy on Nerve Repair Using Red and Infra-red Diode Lasers in Maxillofacial Region (A Randomized Clinical Trial)
- ClinicalTrials.gov ID
- NCT07403695
- Acronym / sponsor ID
- 00010556- 0008839
- Conditions
- Nerve Injury
- Keywords
- laser therapy, photobiomodulation, nerve injury
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- mona orabyUniversity, hospital or other
- Study start
- 18 Mar 2025 (actual)
- Primary completion
- 18 Jan 2026 (actual)
- Study completion
- 18 Jan 2026 (actual)
- First posted
- 11 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Peripheral nerve injury is a major concern that drastically affects the patient's quality of life. Nowadays, several treatment options are available, including medical treatments, surgical intervention, and others. However, the trending photobiomodulation effect of laser therapy is attracting many dental professionals due to its promising results on nerve rehabilitation.
The study is intended to assess and compare laser photobiomodulation using red and infra-red diode lasers on the repair of nerve injury in the maxillofacial region.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 635 wavelength | Experimental | Device: 635 wavelength |
| 980 wavelength | Active comparator | Device: 980 wavelength |
Who may qualify
- Ages
- 20 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Patient aged range from 20-50 years old
- Patient suffering from nerve injury in the maxillofacial region for a period of 6 months or more without improvement.
Key exclusion criteria (1 listed)
- 1- Patient had undergone micro-neurosurgery to correct neurosensory deficit.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 635 wavelength635 wavelength laser | Device | 635 wavelength |
| 980 wavelength980 wavelength laser | Device | 980 wavelength |
Primary outcome
visual analogue scale
Time frame: 1,2,4,8,12 weeks
from 1- 10 1 means no pain 10 means worst pain
1 secondary outcome
clinical neurosensory test
Time frame: 2,4,8,12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Nerve Injury
Not yet recruitingObservational study
Postural Control and Balance Performance in Patients With Carpal Tunnel Syndrome
Carpal Tunnel Syndrome (CTS), Postural Assessment
Recruiting
SIRI Levels Following PENG Block in Pediatric Hip Surgery
Hip Dysplasia
RecruitingPhase 4
PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery
Hip Disease, Hip Dysplasia
Recruiting
Transcutaneous Tibial Nerve Stimulation in Acute Spinal Cord Injury
Spinal Cord Injury, Acute
Recruiting
Acute Genital Nerve Stimulation for Neurogenic Bowel Dysfunction in Individuals Living With Spinal Cord Injury
Fecal Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mona S Oraby principal investigator
Alexandria University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 635 wavelength and 980 wavelength in people with Nerve Injury, run by mona oraby at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
visual analogue scale (time frame: 1,2,4,8,12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Feb 2026.